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Visual analogue scale (VAS)Abstract Background: Osteoid osteoma (OO) is a readily treatable, painful benign bone tumor
that preferentially afﬂicts young patients. Computed tomography (CT)-guided percutaneous
radiofrequency ablation (RFA) treatment has been accepted since 1992 as a noticeably safe and
minimally invasive treatment option for OO.
Objective: To prospectively analyze the factors that may affect time to pain relief post CT-guided
percutaneous RFA treatment of OO. These factors include patient’s age, sex, amount of sclerosis sur-
rounding the nidus, the relation to nearby joint and the number of muscles that have to be traversed.
Materials and methods: This study was conducted on 30 patients diagnosed to have OO on the basis
of clinical and radiological criteria. All patients were treated by CT-guided percutaneous RFA. Pain
was evaluated after the procedure daily for one week using a visual analogue scale (VAS)with 0 denot-
ing no pain and 10 the worst pain imaginable.Moreover, time to pain relief was analyzed in relation to
patient’s age and sex, the amount of sclerosis surrounding the nidus, the relation to nearby joint and
the number of muscles that have to be traversed to reach the lesion.
Results: There was a highly signiﬁcant statistical difference (p= 0.001) between the mean time to
pain relief in OOs with variable amount of sclerosis surrounding the nidus. On the contrary, there
was no signiﬁcant statistical difference considering patient’s sex (p= 0.654), relation to nearby joint
(p= 1.0) or number of muscles that have to be traversed (p= 0.108) in relation to time to pain relief.
Considering patient’s age, there was a signiﬁcant positive correlation (p= 0.013) and (r= 0.446)
between patient’s age and time to pain relief. In addition, there was a highly signiﬁcant positive cor-
relation (p= 0.0001) and (r= 0.636) between the amount of sclerosis surrounding the nidus and time
to pain relief. Eventually, the amount of sclerosis surrounding the nidus was shown to be a highly sig-
niﬁcant independent factor affecting time to pain relief.
398 R. Refaat, G. NiaziConclusion: The amount of sclerosis surrounding the nidus of osteoid osteoma is the most effectual
factor for time to pain relief post CT-guided percutaneous radiofrequency ablation treatment.
 2015 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Osteoid osteoma (OO) is a painful benign bone tumor of the
young (1). It can affect any bone (2). The condition was ﬁrst
described in 1930 by Bergstrand (3) and Jaffe (4) ﬁrst character-
ized osteoid osteoma as a discrete clinical entity in 1935.
Osteoid osteoma is the third most common benign bone tumor
(5) representing approximately 12% of benign bone tumors (6).
Surgery, conservative treatment with non-steroidal anti-in-
ﬂammatory drugs (NSAIDs) and percutaneous interventions
are potential options for the treatment of OO. Surgery is
frequently associated with major morbidity and a prolonged
period of recovery (especially after en-bloc resection of osteoid
osteoma in weight bearing bones), while, long-term drug
administration may result in gastrointestinal side effects and
is not well tolerated by patients (7).
Alternatively, Rosenthal et al. (8) described in 1992 the ﬁrst
successful clinical application of computed tomography (CT)-
guided radiofrequency ablation (RFA) in the treatment of
osteoid osteoma. RFA aims at the precise delivery of heat to
the target tissue. High-frequency alternating current transmit-
ted through the radiofrequency ablation electrode induces
local ionic agitation and frictional heat resulting in coagulation
necrosis (9). Currently, CT-guided RFA has been accepted as a
demonstrably safe, minimally invasive and cost-effective treat-
ment for OO (10).
There are many studies assessing the clinical outcome of
CT-guided percutaneous RFA in osteoid osteoma.
Nevertheless, to the best of our knowledge, there is lack of stu-
dies concerning the factors affecting time to pain relief post
CT-guided RFA treatment of osteoid osteoma. To target this
veiled issue, we aimed in this study to analyze the following
factors in relation to time to pain relief: patient’s age and
sex, the amount of sclerosis surrounding the nidus, the relation
to nearby joint and the number of muscles that have to be tra-
versed to reach the lesion.Fig. 1 Axial CT of the leg shows a cortical osteoid osteoma
located along the posterior aspect of the tibia with a clearly seen
radiolucent nidus surrounded by marked sclerosis and thickened
cortex.2. Materials and methods
2.1. Patients
This prospective study was conducted from April 2012 to June
2014 in which 30 eligible consecutive patients were enrolled.
These patients were diagnosed to have OO on the basis of
clinical and radiological criteria. The clinical criteria included
focal bone pain at the tumor site that was worse at night
and pain relief after administration of oral non-steroidal anti-in-
ﬂammatory drugs (NSAIDs) (e.g., aspirin). This was in addition
to joint functional impairment in the form of decreased range of
movement if the lesion was related to nearby joint. The typical
radiological criteria comprised clear depiction of a radiolucent
nidus equal to or smaller than 1.5 cm in diameter with surround-
ing bony sclerosis and cortical thickening on CT (Fig. 1).The exclusion criteria in this study were diagnoses other
than OO and insufﬁcient patient data. Additionally, patients
who had previously undergone surgical procedures for the
lesions were excluded from our study and patients with lesions
located in the hand or in the posterior neural arch of the
vertebrae were excluded because of the risk to injure the adja-
cently located neural structures. We did not perform biopsy
prior to or during the RFA procedure. Our study protocol
was approved by the Committee of Ethics. All patients or their
legal guardians gave written informed consent after extensive
explanation of the planned therapeutic intervention.
2.2. CT-guided percutaneous RFA technique
Before the procedure, we conﬁrmed that prothrombin time
and international normalized ratio (INR) obtained within
24 h of the procedure were normal. All patients underwent
physical examination immediately prior to treatment to deter-
mine the site of focal bone pain. An anesthetist’s evaluation
was also carried out. For lesions in lower limbs, RFA was per-
formed under spinal anesthesia, whereas, general anesthesia
was preferred for lesions in upper limbs. Dispersive grounding
pads were applied on the patient’s thighs, in proper alignment
with each other and with good skin contact; both pads were
placed at approximately equal distance from the site of abla-
tion and as close to the ablation site as possible so as to allow
the shortest current path through the patient. Towels were
placed between the trunk and the patient’s arms on either side
and between the legs to reduce the risk of skin to skin contact
burns.
All RFA procedures were performed in the CT room under
CT guidance (Hi-Speed CT system, GE Medical Systems).
Patients were positioned on the CT table in a prone, oblique
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osteoma. After patient positioning and ﬁxation, skin prepara-
tion and proper sterilization, contiguous CT scans with a sec-
tion thickness of 1–3 mm were obtained for precise localization
of the nidus. Under CT guidance, a 20-gauge needle was then
inserted for periosteal anesthesia by injecting 2–5 mL of 0.5%
bupivacaine hydrochloride. The position of the lesion, ease of
access and the relationship with adjacent neurovascular
structures were assessed. This was followed by a small skin
incision at the puncture site and then, an osseous access to
the nidus was established with the use of an 11-gauge, 11 cm
long hollow bone biopsy needle (BON-CORE bone biopsy
needles, Cook).
Generally, the shortest distance through the bone was
selected for access (Figs. 2–6). Conversely, if such approach
was technically difﬁcult (necessitating a steeply oblique
approach to the bone surface that would cause the needle skid-
ding off the cortex) or unsafe (in proximity to neurovascular
structures or joint capsule), the lesion was approached from
the opposite side of the bone (Fig. 7). To minimize the possibil-
ity of thermal burns, the tip of the needle was inserted deep so
that it did not lie near the skin surface.
RF ablation was performed with use of a single straight
rigid electrode with an outer diameter of 1 mm, an effective
length of 7–10 mm and an internal thermistor for simultaneous
temperature measurement (Cool-tip radiofrequency electrodes;
Radionics, Burlington, MA). The electrode was introducedA
Fig. 2 (A) Axial CT of the femur in the supine position shows a subp
of the femur in the supine position after placing the RF needle within
A
Fig. 3 (A) Axial CT of the acetabulum in the prone position shows a m
CT of the acetabulum in the prone position displays the RF needle trthrough the hollow biopsy cannula (coaxial system). The unin-
sulated portion of the electrode was then exposed and posi-
tioned within the center of the nidus and the hollow cannula
of the bone biopsy system was withdrawn to the skin surface
to avoid any contact between it and the active tip of the RF
electrode as such contact may conduct heat to the skin surface
and results in skin burn. After connection of the electrode with
an RF generator (Model RFG-3B; Radionics, Burlington,
MA), the tip of the electrode was heated to 90 C for a period
of 5–6 min. After thermocoagulation and removal of the
electrode, approximately 2–4 mL of 0.5% bupivacaine
hydrochloride was injected directly into the hole to reduce
post-procedure pain.
A sterile drape of the skin was performed. After the proce-
dure, a small pressure dressing was applied at the percutaneous
puncture site. Also prophylactic antibiotic regimen was pre-
scribed to guard against cutaneous infection and osteomyelitis,
which consisted of intra-muscular injection of ceftazidime
(FORTUM) 1 g. Post-procedural CT was performed to
conﬁrm the absence of soft tissue swelling and hematoma.
Short-term outcome was evaluated to detect procedure-related
problems. Each patient was examined in the recovery room.
The procedure site and the location of the grounding pads
were evaluated for evidence of bleeding, swelling and burns.
Neurovascular integrity was assessed and the patient was
asked about pain. If necessary, a brief course of analgesic
therapy was prescribed.B
eriosteal osteoid osteoma located in the neck region. (B) Axial CT
the nidus.
B
edullary osteoid osteoma with no surrounding sclerosis. (B) Axial
aversing two muscles to be placed within the nidus.
A B
Fig. 4 (A) Axial CT of the acetabulum in the prone position shows a medullary osteoid osteoma with no surrounding sclerosis. (B) Axial
CT of the acetabulum in the prone position displays the RF needle traversing two muscles to be placed within the nidus.
A B 
Fig. 5 (A) Axial CT of the left upper humerus in the prone position shows a cortical osteoid osteoma located in the postero-lateral
aspect of the left upper humerus with no surrounding sclerosis. (B) Axial CT of the left upper humerus in the prone position displays the
RF needle traversing one muscle to be placed within the nidus.
A B
Fig. 6 (A) Axial CT of the femur in the supine position shows a cortical osteoid osteoma located in the anterior aspect of the right femur
neck with minimal surrounding sclerosis. (B) Axial CT of the femur in the supine position displays the RF needle traversing two muscles to
be placed within the nidus.
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A B
Fig. 7 (A) Axial CT of the leg shows a cortical osteoid osteoma in the lateral tibial aspect with marked sclerosis. (B) CT scan of the leg
shows an approach to the lesion in the lateral tibial cortex through the unaffected medial cortex.
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ablation session. The duration of the procedure (from the time
the patient entered the CT room and including the time taken
for anesthesia) was approximately 90 min. All patients were
allowed to resume their full physical activity after 72 h from
the procedure wherever the lesion was. Procedures were
considered to be technically successful if the electrode was
placed centrally within the nidus so that no portion of the
lesion was more than 5 mm away from the exposed tip and
if the target temperature was reached and maintained.
Clinical success was deﬁned as complete relief from pain and
return to normal activities without additional treatment within
1 week of the procedure.
2.3. Evaluation method
After RF ablation, we interviewed all patients by telephone
everyday for one week after the procedure to determine the
clinical success of the procedure. This was achieved through
inquiring about resolution of post-procedure pain, the use of
any analgesic medications and late complications (skin burn,
infections, wound problems). The patients had to quantify
their pain on a visual analogue scale (VAS) from 0 (no pain)
to 10 (worst possible pain). Relief of pain through the use of
pain medications was scored on a scale of 0% (no relief) to
100% (complete relief). Each patient was asked to answer
these questions with respect to the lesion. Eventually, we ana-
lyzed the following factors in relation to time to pain relief:
patient’s age and sex, the amount of sclerosis surrounding
the nidus, the relation to nearby joint and the number of mus-
cles that have to be traversed to reach the lesion.
2.4. Statistical analysis
All statistical procedures were carried out using SPSS version
15 for Windows (SPSS Inc., Chicago, IL, USA). Continuous
variables were expressed as mean ± standard deviation (SD)
or median according to data distribution and both number
and percentage for categorical variables. Student t test and
ANOVA test were used to compare quantitative data with
Bonferroni post-hoc test for pairwise comparison. Whereas,
Pearson and Spearman’s correlation were used according to
data distribution to assess the correlation between time to pain
relief and other quantitative data. The probability of error(p value) at 0.05 was considered signiﬁcant, while, at 0.01
and 0.001 was considered highly signiﬁcant.
3. Results
The patients enrolled in our study had a mean age of
20.9 ± 6.5 years and age range of 6–39 years. There were 22
male patients (73.3%) and 8 female patients (26.7%). OOs
were located in femur (n= 16), tibia (n= 5), ﬁbula (n= 1),
talus (n= 2), navicular bone (n= 1), acetabulum (n= 2),
humerus (n= 2) and radius (n= 1). Considering the anatomi-
cal location of the tumor in bone, OOs were cortical (n= 24),
medullary (cancellous) (n= 4) and subperiosteal (n= 2)
(Table 1).
The joint function was signiﬁcantly impaired by the pres-
ence of OO related to nearby joint in 10 of 30 patients
(33.3%): 7, 2 and 1 in hip, ankle and shoulder joints respec-
tively. Alternatively, 20 patients (66.7%) had OOs not related
to nearby joint. Regarding the amount of sclerosis surrounding
the nidus, no sclerosis was noted in 9 OOs (30%), while, mild
and marked sclerosis were noted in 16 (53.3%) and 5 (16.7%)
OOs respectively. The number of muscles that have to be tra-
versed was 1 muscle in 7 OOs (23.3%) and 2 muscles in 15 OOs
(50%). On the other hand, no muscles were traversed in 8 OOs
(26.7%) (Table 2).
Describing the mean pain score each day post-ablation for
1 week, mean pain score at day 1 was 7.8 ± 1.3, at day 2 was
4.9 ± 2.9, at day 3 was 3.4 ± 2.9, at day 4 was 2.2 ± 2.8, at
day 5 was 1.4 ± 1.9, at day 6 was 0.5 ± 0.8 and at day 7
was 0. No persistence of pre-procedural pain was noted. The
procedure was technically and clinically successful in all
patients.
There was a highly signiﬁcant statistical difference between
the mean time to pain relief in OOs with variable amount of
sclerosis surrounding the nidus (p= 0.001). As OOs
with marked sclerosis had higher mean time to pain relief
(6.6 ± 0.5 days) compared to OOs with no sclerosis
(3.1 ± 1.5 days) and OOs with mild sclerosis (4.6 ± 1.5 days)
(Fig. 8). There was a highly signiﬁcant statistical difference
(p= 0.001) between OOs with no sclerosis versus OOs with
marked sclerosis. Also, there was a statistically signiﬁcant dif-
ference (p= 0.048) between OOs with no sclerosis versus OOs
with mild sclerosis and OOs with mild sclerosis versus OOs
with marked sclerosis (p= 0.033).
Table 1 Overview of patients’ characteristics.
Patients, n 30
Age (years), mean (range) 20.9 ± 6.5 (6–39)
Sex, n (%)
Male 22 (73.3%)
Female 8 (26.7%)
Lesion location, n
Femur 16
Tibia 5
Fibula 1
Talus 2
Navicular bone 1
Acetabulum 2
Humerus 2
Radius 1
Anatomical location
Cortical 24
Medullary (Cancellous) 4
Subperiosteal 2
Table 2 The number and percentage of osteoid osteomas
regarding relation to nearby joint, amount of sclerosis
surrounding the nidus and number of muscles that have to be
traversed.
Relation to nearby joint, n (%)
Related 10 (33.3%)
Not related 20 (66.7%)
Amount of sclerosis surrounding the nidus, n (%)
No sclerosis 9 (30%)
Mild sclerosis 16 (53.3%)
Marked sclerosis 5 (16.7%)
Number of muscles that have to be traversed, n (%)
None 8 (26.7%)
One muscle 7 (23.3%)
Two muscles 15 (50%)
0
1
2
3
4
5
6
7
M
ea
n 
tim
e 
to
 p
ai
n 
re
lie
f (
da
ys
)
No sclerosis     Mild sclerosis   Marked sclerosis
Amount of sclerosis surrounding the nidus
Fig. 8 The relationship between the amount of sclerosis
surrounding the nidus and mean time to pain relief.
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considering patient’s sex (p= 0.654), the relation to nearby
joint (p= 1.0) or the number of muscles that have to be tra-
versed (p= 0.108) in relation to time to pain relief. The mean
time to pain relief in male and female patients was 4.4 ± 1.7
and 4.8 ± 2.3 days respectively. The mean time to pain relief
in OOs not related to nearby joint was 4.5 ± 2 days and the
mean time to pain relief in OOs related to nearby joint was
4.5 ± 1.5 days. The mean time to pain relief in OOs with no
muscles to be traversed was 4.6 ± 2 days, while, the mean time
to pain relief in OOs with 1 muscle that have to be traversed was
3.3 ± 1.5 days and the mean time to pain relief in OOs with 2
muscles that have to be traversed was 5.0 ± 1.6 days.
In addition, there was a highly signiﬁcant positive cor-
relation (p= 0.0001) (r= 0.636) between the amount of
sclerosis surrounding the nidus and time to pain relief
(Fig. 9). Considering patient’s age, there was a signiﬁcant posi-
tive correlation (p= 0.013) (r= 0.446) between patient’s age
and time to pain relief (Fig. 10).
Eventually, multivariate regression model was used to
study the effect of the following independent factors: patient’s
age and sex, the amount of sclerosis surrounding the nidus, the
number of muscles that have to be traversed and the relation to
nearby joint on time to pain relief. After adjustment to other
factors, the amount of sclerosis surrounding the nidus was
shown to be a highly signiﬁcant independent factor affecting
time to pain relief. Patients having OO with mild sclerosis
had a prolongation of time to pain relief by 1.8 day
(p= 0.005) compared to those with no sclerosis and patients
having OO with marked sclerosis had a prolongation of time
to pain relief by 4.1 day (p= 0.0001) compared to those with
no sclerosis. On the other hand, patient’s age and sex, the
relation to nearby joint and the number of muscles that have
to be traversed were shown to be non signiﬁcant independent
factors affecting time to pain relief.
4. Discussion
Osteoid osteomas can result in extreme disability secondary to
unrelenting pain despite being benign (11,12), additionally,Fig. 9 Scatter diagram plots time to pain relief against the
amount of sclerosis surrounding the nidus.
Fig. 10 Scatter diagram plots time to pain relief against patient’s
age.
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may be present for several years before clinical presentation
(13). It is not related to physical exercise, but worsens with rest
(15) and has a characteristic nocturnal exacerbation (15,16).
Several researches studying osteoid osteomas have been
published; yet, the majority of these studies are limited to the
clinical outcome of a speciﬁc treatment technique. None of
these studies was directed to the factors that may affect time
to pain relief following the treatment.
Pain is thought to be due to local inﬂammation and vasodi-
latation; the consequence of very high levels of prostaglandins
(PGs) expressed by the tumors. The increased production of
prostaglandins by osteoid osteomas implicates enzyme; the
cyclooxygenase-2 (COX-2) that is blocked by NSAIDs (17).
Nerve ﬁbers seen in the reactive zone around the nidus and/
or in the nidus are also thought to play a key role in mediation
of pain in osteoid osteoma (18,19).
We found that there was a highly signiﬁcant statistical dif-
ference (p= 0.001) between the mean time to pain relief in
OOs with variable amount of sclerosis surrounding the nidus.
As OOs with marked sclerosis had higher mean time to pain
relief (6.6 ± 0.5 days) compared to OOs with no sclerosis
(3.1 ± 1.5 days) and OOs with mild sclerosis (4.6 ± 1.5 days).
On the contrary, there was no signiﬁcant statistical difference
considering patient’s sex, the relation to nearby joint or the
number of muscles that have to be traversed in relation to time
to pain relief. In addition, there was a highly signiﬁcant positive
correlation (p= 0.0001) and (r= 0.636) between the amount
of sclerosis surrounding the nidus and time to pain relief.
Eventually by using multivariate regression model, the amount
of sclerosis surrounding the nidus was shown to be a highly sig-
niﬁcant independent factor affecting time to pain relief.
Our ﬁnding could be explained by the fact that osteoid
osteoma causes an intense and chronic inﬂammatory response
in the surrounding tissues (20–22) with a periosteal reaction,
sclerosis of bone and synovitis (21) because of the production
of prostaglandins by the tumor (23,24) which regresses
spontaneously after removal of the nidus (21). Thus, as the pro-
duction of prostaglandins increases, sclerosis will increase and
pain will increase as well owing to the fact that prostaglandins
mediate the pain of osteoid osteomas (17). In addition, muchsclerosis requires a more technically demanding effort to
reach the nidus and hence, time to pain relief increases.
Correspondingly, as mentioned before, nerve ﬁbers seen in the
reactive zone around the nidus (18,19) are thought to play a
key role in mediation of pain in osteoid osteomas.
Although, potential procedural complications include
thermal skin injury (25), neural injury, bleeding or infection
at the skin entry site (26) and fractures of bones with lesions
treated using RFA (27), no complications occurred in our
study. It is well-established that percutaneous thermal ablation
(PTA) has success rate close to 100% (1). Similarly, we
achieved in the current study a clinical success rate of 100%.
All patients in the current study were typically diagnosed by
CT and there was no need to perform MRI corresponding to
other researchers (10,16) who used the same diagnostic tool
to establish the diagnosis of osteoid osteoma. Moreover, we
did not perform biopsy prior to RFA in this study as we share
the prevailing opinion that the diagnosis of osteoid osteoma is
mainly on the basis of the patient’s history and radiological
data (28). This is in addition to the opinion that histological
conﬁrmation of the diagnosis of osteoid osteoma is not neces-
sary in typical cases (29) due to a remarkable amount of false
negative ﬁndings in clinically and morphologically unambigu-
ous cases of osteoid osteoma (7). Nevertheless, it is recom-
mended in equivocal cases (29). Similarly, post-treatment CT
or MR imaging was not performed and we depended upon
pain relief which was sufﬁcient to evaluate treatment efﬁciency,
since, speciﬁc imaging has proved ineffective to monitor the
evolution after treatment (30).
Fatefully, to the best of our knowledge, there is lack of
studies concerning the factors affecting time to pain relief post
CT-guided percutaneous RFA treatment of osteoid osteoma.
For that reason, we were not capable to compare our results
with results of similar studies. Then, we recommend further
similar studies with a larger population to conﬁrm or refute
our ﬁndings regarding the factor inﬂuencing time to pain relief
following CT-guided percutaneous radiofrequency ablation
treatment of osteoid osteoma.
To conclude: Time to pain relief post CT-guided percuta-
neous radiofrequency ablation treatment of osteoid osteoma
is markedly affected by the amount of sclerosis surrounding
the nidus. This is in contradiction to patient’s age and sex,
the relation to nearby joint and the number of muscles that
have to be traversed to reach the lesion.
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